SCHEMBL3084757

SCHEMBL3084757

CCc1ccc(Cc2c(Cl)[nH]c3ccccc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.50
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
NR4A2 P43354 1/20 0.42
MAPT P10636 2/20 0.41
PRNP P04156 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TUBB4A P04350 2/20 0.41
TUBB P07437 2/20 0.41
TUBA3C P0DPH7 2/20 0.41
TUBA1B P68363 2/20 0.41
TUBA4A P68366 2/20 0.41
TUBB4B P68371 2/20 0.41
TUBB3 Q13509 2/20 0.41
TUBB2A Q13885 2/20 0.41
TUBB8 Q3ZCM7 2/20 0.41
TUBA3E Q6PEY2 2/20 0.41
TUBA1A Q71U36 2/20 0.41
TUBA1C Q9BQE3 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3078541 0.82 HTT (0.57) KIF11CTSVCTSLMAPTALDH1A1
SCHEMBL6993933 0.78 MAPT (0.49) KIF11MAPTPRNPALDH1A1TUBB4A
SCHEMBL31696757 0.73 ALDH1A1 (0.46) NR4A2MAPTALDH1A1KDM4EHTT
SCHEMBL7495375 0.72 HTR2A (0.58) MAPTPRNPKDM4ETUBB4ATUBB
SCHEMBL5774983 0.71 MAPT (0.51) MAPTPRNPALDH1A1KDM4ETUBB4A
SCHEMBL6992348 0.71 TUBB4A (0.57) MAPTPRNPKDM4ETUBB4ATUBB
SCHEMBL6479409 0.71 KIF11 (0.46) KIF11CTSVCTSLMAPTALDH1A1
SCHEMBL30288451 0.70 CHRNB2 (0.46) NR4A2MAPTALDH1A1KDM4EHTT
SCHEMBL30288465 0.70 HTR2A (0.67) MAPTCYP3A4TSHRDRD2HTR2A
SCHEMBL30288454 0.70 CHRNB2 (0.46) NR4A2MAPTALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR KIF11 3252/4885CTSV 2963/4885CTSL 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.